The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
暂无分享，去创建一个
A. Hervás | D. Salom | P. Udaondo | A. Navarro-Navarro | J. Martínez-Toldos | C. Fernández-Martínez | L. Gutiérrez-Arias | R. Rodrigo
[1] E. Kankaanpää,et al. Cost‐effectiveness of treating wet age‐related macular degeneration at the Kuopio University Hospital in Finland based on a two‐eye Markov transition model , 2016, Acta ophthalmologica.
[2] N. Bressler,et al. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. , 2016, JAMA ophthalmology.
[3] Usha Chakravarthy,et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial , 2014, BMJ Open.